Heidelberg, Germany, October 15, 2026 – AaviGen GmbH today announced the appointment of Eric Goossens as Senior Vice President Corporate Development and member of the Leadership Team, reporting to CEO Prof. Patrick Most, effective October 15, 2026.
Eric Goossens has been closely associated with AaviGen since 2021 as a member of its Scientific Advisory Board. With his appointment to the Leadership Team, he will step down from his advisory role and take on executive responsibility for Corporate Development. In his new role, Goossens will contribute to AaviGen’s corporate and strategic development as the company advances its pipeline of heart-specific gene therapies.
Prof. Patrick Most, Co-Founder and CEO of AaviGen, commented: “Eric has been a trusted advisor to AaviGen since 2021 and has developed a deep understanding of our science, technology and ambitions. We are delighted that he is now joining our Leadership Team in an executive capacity. As AaviGen continues to advance its pipeline and technology, Eric’s experience in corporate development and strategic partnering will be instrumental in helping us build the relationships and strategic framework required for our next phase of development.”
Eric Goossens, SVP Corporate Development, commented: “Having supported AaviGen as a Scientific Advisory Board member since 2021, I have had the opportunity to follow the evolution of the company, its science and its technology closely. I am therefore particularly excited to now join the Leadership Team and contribute in an executive capacity. I strongly believe in the potential of transformative, heart-specific gene therapy to change the treatment paradigm for patients with serious cardiac disease. I look forward to working with Patrick and the entire AaviGen team to translate the company’s scientific innovation into strategic opportunities and partnerships and, ultimately, meaningful impact for patients.”
About AaviGen
AaviGen was founded on the insight that successful cardiac gene therapy depends on the optimized delivery of genetic therapeutics to the diseased heart. Its human-to-human, cardiac-targeted AAV vector technology sets new standards for precision, efficacy, and safety in the treatment of both acquired and inherited heart diseases. AaviGen’s scientific approach is supported by numerous peer-reviewed publications and builds on the founders’ strong track record of scientific innovation in the diagnosis and treatment of heart disease, including the development of gene therapy medicines. For more information, please visit: www.aavigen.com.